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Abstract
Hepatocellular carcinoma (HCC) occurs mostly in individuals with cirrhosis, which is why the guidelines of 
the most important scientific societies indicate that these patients are included in surveillance programs 
through the repetition of an ultrasound examination every 6 months. The aim is to achieve early identification 
of the neoplasia in order to increase the possibility of curative therapies (liver transplantation, surgery or local 
ablative therapies) and to increase patient survival. HCC nodules arising in cirrhotic livers show characteristic 
angiographic behavior that can be evaluated with dynamic multidetector computed tomography and dynamic 
magnetic resonance imaging (MRI). However, the use of these techniques in real life is often hindered by the 
lack of uniform terminology in reporting and in the interpretation of the exams reflected in the impossibility of 
comparing examinations performed in different centers and/or at different times. Liver Imaging Reporting and 
Data System® was created to standardize reporting and data collection of computed tomography and MRI for 
HCC. In some cases HCC arises in patients with healthy livers and, although there is evidence that angiographic 
behavior is not different from cirrhotic patients in this clinical situation, the guidelines still indicate the execution of 
a biopsy. Frequent use of palliative therapeutic techniques such as transarterial chemoembolization, transarterial 
radioembolization or administration of antiangiogenic drugs (sorafenib) poses problems of interpretation of the 
therapeutic response with repercussions on the subsequent choices that have been attempted to resolve with the 
use of stringent criteria such as Modified Response Evaluation Criteria In Solid Tumors.
Keywords: Hepatocellular carcinoma, cirrhosis, ultrasonography, magnetic resonance imaging, multidetector computed 
tomography, Liver Imaging Reporting and Data System, Modified Response Evaluation Criteria In Solid Tumors
INTRODUCTION
The diagnosis of hepatocellular carcinoma (HCC) can be addressed in two different clinical settings. A first 
context, rarely, is that of the patient with a healthy liver. In this scenario, patients do not undergo routine 
monitoring and tumors are often large with possible vascular involvement. In these patients, performing 
a liver biopsy is often necessary for diagnostic confirmation. A second, frequently, is that of patients with 
chronic liver disease (cirrhosis or advanced fibrosis) under regular ultrasound surveillance[1]. The goal of 
surveillance and screening is to reduce mortality[2]. For the aforementioned reasons HCC meets the criteria for 
developing a surveillance program and the use of ultrasound as a screening tool is accepted by major scientific 
societies[3-5]. In many studies the 3-year survival rate varies between 50.8% and 45.6% in patients under 
surveillance and 27.9% and 28.8% in those not screened. Even after correction for lead time bias, the three-year 
survival is better in patients undergoing ultrasound surveillance: 39.7% vs. 29.1%. It is likely that the increased 
survival in patients undergoing surveillance is linked to an increase in early detection of HCC in patients 
screened (OR of 2.11; 95% CI, 1.88-2.33) and therefore of the use of curative treatments (61.8% vs. 38.2%)[5].
ULTRASONOGRAPHY AND CONTRAST-ENHANCED ULTRASONOGRAPHY
Efficacy of detection of HCC with ultrasound varies widely and in cirrhotic patients presents with a 
sensitivity of 33%-96%[6] while specificity reach over 90%[7]. The identification of small HCC nodules in 
cirrhotic liver with a coarse parenchymal pattern is not easy, therefore a skilled operator must work with 
adequate equipment, preferably in dedicated centers. In gray-scale ultrasound small HCCs typically appear 
as a hypoechoic lesion. In some cases increased echogenicity may be present due to adipose degeneration. 
Sometimes the hypoechoic nodule may present a hyperechoic focus which is suggestive of development of 
HCC within a dysplastic nodule (nodule in nodule phenomenon)[8].
But not all nodules identified with ultrasound in patients with chronic liver disease (cirrhosis or advanced 
fibrosis) undergoing surveillance are HCCs. In this context, the role of imaging is to differentiate the 
nodules of HCC from other malignant lesions (intrahepatic cholangiocarcinoma and metastasis) and non-
malignant (e.g., regenerative nodules, low and high grade dysplastic nodules, confluent fibrosis, angiomas, 
etc.) that can be found in the cirrhotic liver. In oncology, the diagnosis of cancer generally requires 
histological assessment; from this point of view HCC is an exception since a non-invasive diagnosis can 
be achieved with imaging alone in these high-risk populations. The peculiar angiographic behavior of the 
HCC nodules in a cirrhotic liver characterized by the presence of the wash-in during the arterial phase 
and by the wash-out during the venous and late phases, represents the diagnostic hallmarks of HCC. 
These characteristics are able to provide a reliable diagnosis of HCC in high-risk patients affected by liver 
cirrhosis or with advanced fibrosis, and represent the background for the development, by Western and 
Asian scientific societies, of different algorithms for non-invasive diagnosis of HCC[3,4,9,10]. The recommended 
imaging methods are computed tomography (CT) and MRI with contrast agents. Diagnostic algorithms 
of American Association for the Study of Liver Diseases (AASLD) and European Association for the Study 
of the Liver (EASL) guidelines adopt a strategy dependent on the size of the lesion. Nodules smaller than 1 
cm are considered too small to be characterized and both guidelines recommend ultrasound monitoring 
every three (AASLD) or four months (EASL). As for the diagnosis of nodules with a diameter greater than 
2 cm, both guidelines recommend only one imaging method. For nodules with a diameter of 1-2 cm, the 
statements differ, as the American guidelines recommend the same approach used for lesions larger than 
2 cm (only one contrast method is sufficient), while the European guidelines contemplate the concordance of 
two consecutive images if these cases are not followed in centers with substantial “expertise”.
Consequently, in cirrhotic patients, biopsy is indicated only in cases where nodules do not present 
contrasting features typical of HCC. However, the increasing knowledge about the immunohistochemical 
and molecular characteristics of HCC may bring biopsy to the forefront in order to select patients who could 
gain the most benefit from target-driven HCC treatments[11].
In conclusion, the identification of a liver focal lesion greater than 1 cm in the course of surveillance of 
patients at risk with ultrasonography imposes the study of the nodule vascularization through the use of 
Page 2 of 16                                           de Santis et al. Hepatoma Res 2019;5:1  I  http://dx.doi.org/10.20517/2394-5079.2018.65
multidetector computed tomography (MDCT) or multi-phase nuclear magnetic resonance imaging (MRI) 
with contrast agents.
Contrast-enhanced ultrasound (CEUS) may be a useful imaging modality for the noninvasive diagnosis of 
small, newly detected liver nodules during surveillance of cirrhotic patients[12]. Ultrasound contrast agents 
(“microbubbles”) comprise an albumen or phospholipid shell containing a stable perfluorocarbon or sulphur 
hexafluoride gas. They are predominantly blood-pool agents, as the encapsulated microbubbles are small 
enough to pass through both pulmonary and systemic circulation after intravenous injection and durable 
enough to re-circulate for several minutes[13]. CEUS can also be utilized in the presence of renal impairment 
and can be performed at the time in which the lesion is discovered but it does not eliminate the need for CT 
and/or MRI in order to characterize the lesion and to stage the disease[14]. CEUS was inserted as a method 
for characterizing nodules arising in cirrhotic livers, in the 2005 AASLD guidelines[15] but was subsequently 
eliminated in 2011, partly due to lack of availability of ultrasound contrast in the USA and partly due to false 
positive diagnoses in patients with intra-hepatic cholangiocarcinoma[3].
CT AND MRI
As already mentioned, the identification of a liver focal lesion greater than 1 cm in the course of surveillance 
with ultrasonography of patients at risk imposes the study with higher level image techniques such 
as MDCT or MRI with an extracellular contrast medium (iodized compound or gadolinium-based 
compounds: gadoteric acid, gadopentetic acid, gadodiamide, gadoteridol, gadobutrol) that remain in the 
extracellular space and allows the characterization of blood flow. Multi-phase MRI may be performed also 
with an hepatospecific contrast agents such as gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid 
or Gd-EOB-DTPA, gadobenate dimeglumine or Gd-BOPTA, which is captured by “healthy” hepatocytes 
and excreted in the biliary tract, or by iron oxide particles (SPIO) with superparamagnetic activity, which 
are captured by Kupffer cells located in the non-neoplastic hepatic parenchyma and in benign lesions but not 
in malignant ones.
The goals of the evaluation by MRI or MDCT of a hepatic nodule in a patient with liver cirrhosis are not 
only the determination of the nature of the lesion but also, in the case of an HCC, the estimate of the hepatic 
extension of the neoplasia and the possible localization in extrahepatic sites in order to propose a treatment 
based on the exact staging of the disease.
There is universal consensus that the diagnosis of HCC can be achieved without biopsy in a situation where 
the pre-test probability is very high, as happens in liver cirrhosis, but there is no consensus as to which 
technique is the best. The angiographic features of HCC are identical in MDCT and MRI, but the latter offers 
a series of additional imaging sequences such as T2-weighted sequences, diffusion-weighted imaging and 
in combination with the use of a hepatospecific contrast agent it can improve diagnostic performance[16-19]. 
However, MRI presents greater technical complexity, longer scan times, greater susceptibility to artifacts, a 
less consistent image quality, higher cost, lower availability, longer scheduling backlogs[20] and its diagnostic 
yield becomes void if the patient is unable to hold his breath, to remain still or presents a high-volume 
ascites. For these reasons the superiority of one method over the other, especially in real-life contexts 
remains uncertain.
In a recent meta-analysis in which MDCT was compared with MRI with an extracellular agent, or MRI 
with gadoxetate disodium, Roberts et al.[20] concluded that the latter showed significantly higher sensitivity 
(0.82; 95% CI, 0.75-0.87 vs. 0.66; 95 % CI, 0.60-0.72) and lower negative likelihood ratio (0.20; 95% CI, 0.15-0.28; 
vs. 0.37; 95% CI, 0.30-0.44) in diagnosis of HCC lesions. Pooled analysis demonstrated that both gadoxetate 
enhanced MRI and extracellular contrast - enhanced MRI provided significantly higher sensitivity and 
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lower negative likelihood ratio than MDCT[20]. However, the authors do not believe there is enough evidence 
to provide definitive recommendation for systematic use of gadoxetate-enhanced MRI or extracellular 
contrast-enhanced MRI over MDCT. In fact, in clinical practice, beyond the diagnostic yield, many other 
factors may guide the choice between modalities, such as the presence of ascites, the patient’s inability to 
hold his or her breath, the severity of cirrhosis and/or a significant hepatic iron overload, and the presence of 
contraindications to the use of contrast agents.
LIVER IMAGING REPORTING AND DATA SYSTEM
The application of the guidelines in real life is often penalized by the lack of uniform terminology in 
reporting and by the excessive variation in the interpretation of the exams causing the impossibility of 
comparing examinations performed in different centers and/or at different times. Liver Imaging Reporting 
and Data System® (LI-RADS®)[21] was created to standardize the reporting and data collection of MDCT and 
MRI for HCC. This method of categorizing liver findings for patients with risk factors for developing HCC 
allows the radiology community to: (1) apply consistent terminology; (2) reduce imaging interpretation 
variability and errors; (3) Enhance communication with referring clinicians; and (4) facilitate quality 
assurance and research.
LI-RADS, was originally released by the American College of Radiology in 2011, and since then revised 
four times. The system was created to be applied to MDCT and MRI in the context of hepatic diseases at 
high risk of developing malignant lesions, such as cirrhosis, chronic hepatitis B or history of current or 
prior HCC. They permit better communication between radiologists and physicians, clearly differentiating 
between lesions definitively benign (LR1, i.e., LI-RADS 1), probably benign (LR2), with intermediate 
probability of being malignant (LR3), with high probability of being malignant but not necessarily HCC 
(LR-M), probably HCC (LR4), and definitively HCC (LR5). The final version of LI-RADS has been published 
online on the American College of Radiology (ACR) website[22]. The assignment to specific categories is 
obtained considering certain “major features”: (1) arterial phase hyperenhancement; (2) size of the lesion; (3) 
portal venous phase wash-out; (4) “enhancing capsule” in portal venous/delayed/transitional phases; and (5) 
speed of growth over a threshold. The “enhancing capsule” is a smooth, uniform, sharp border around the 
lesion, clearly thicker than the fibrous layers of the background regenerative cirrhotic nodules. The threshold 
of growth means an increase in size of a mass by a minimum of 5 mm associated with: ≥ 50% increase in 
size in ≤ 6 months, ≥ 100% increase in size in > 6 months or a previously unseen nodule on MDCT/MRI, 
now ≥ 10 mm, in ≤ 24 months. These “major criteria” must be combined as shown below to ascertain the 
final category [Figure 1]. The use of “ancillary criteria” is at the discretion of the radiologist, and allows for 
recategorization [Figure 2]. In fact, one ancillary feature favoring malignancy, allows for upgrading by one 
category to LR-4 (but can never be used to upgrade to LR-5); on the contrary, one ancillary criterion favoring 
benignity warrants downgrading by one category; the coexistence of one criterion favoring benignity and 
another favoring malignity does not modify the current category. 
LI-RADS are also applicable in judging the response to treatment: even if there is no description of 
treatment-specific features, some general indications are given to carry out the categorization, as illustrated 
in Table 1.
Regarding the category “LR-TR viable”, when the tissue has a thick irregular aspect, the measurement is 
made by taking the longest diameter of the enhancing area, without traversing the non-enhancing area; 
when it has a mass like aspect (and possibly more than one mass), the biggest enhancing area is to be 
measured, by taking its longest diameter. 
Compared to other systems for radiological evaluation of hepatic lesions, LI-RADS has introduced an 
important innovation that is a program of follow-up for each radiological category. Specifically, benign 
Page 4 of 16                                           de Santis et al. Hepatoma Res 2019;5:1  I  http://dx.doi.org/10.20517/2394-5079.2018.65
lesions (LR-1 and LR-2) do not require an adaptation of the normal program of surveillance proposed by the 
guidelines for patients at risk of HCC, so in this condition a MDCT/MRI with extracellular contrast should 
be repeated after 6 months. For lesions at intermediate risk of malignancy (LR-3), it is advised to repeat 
the same imaging examination at 3-6 months; changing the imaging technique is a possible alternative, 
but is not recommended. For LR-M and LR-4, a multisciplinary discussion is required to decide whether 
a biopsy and/or treatment is feasible, otherwise the same imaging examination will be repeated within a 
maximum of 3 months. A multidisciplinary discussion is also proposed for LR-5 to select the best treatment 
option. A special category that needs multidisciplinary evaluation is that of LR-TIV (tumor in vein) which is 
assigned only if the neoplastic nature of the vascular occlusion can unequivocally be determined, combining 
radiological features with serological biomarkers and (if needed) histological aspect. For treated HCC, 
independently from the result obtained, a follow-up every 3 months or less using the same imaging modality 
is suggested. Reporting this last recommendation in clinical practice, a reasonable approach could be that of 
monitoring the treated lesion with ultrasound as well, in order to better guide the timing for the repetition 
of MDCT/MRI on the basis of dimensional or aspect modification of HCC. 
As mentioned before, ultrasound is the screening method indicated by all guidelines for the surveillance of 
patients at risk of developing an HCC. In light of the potential importance of a first detection in ultrasound 
Figure 1. Categories Liver Imaging Reporting and Data System based on the application of major criteria. CT: computed tomography; MRI: 
magnetic resonance imaging; LR: Liver Imaging Reporting and Data System (LI-RADS); APHE: arterial phase hyperenhancement; OPTN: 
Organ Procurement and Transplantation Network; AASLD: American Association for the Study of Liver Diseases; HCC: hepatocellular 
carcinoma
Table 1. Liver Imaging Reporting and Data System criteria to define the response to treatment
Responsecategory Criteria
LR-TR nonviable No lesional enhancement OR
Treatment-specific expected enhancement pattern 
LR-TR equivocal Enhancement atypical for treatment-specific expected enhancement pattern and not meeting criteria for 
probably or definitely viable
LR-TR viable Nodular, masslike, or thick irregular tissue in or along the treated lesion with any of the following:
   Arterial phase hyperenhancement OR
   Washout appearance OR
   Enhancement similar to pretreatment
LR-TR: Liver Imaging Reporting and Data System Treatment Response
de Santis et al. Hepatoma Res 2019;5:1  I  http://dx.doi.org/10.20517/2394-5079.2018.65                                        Page 5 of 16
of nodules suspected of being malignant, ACR has proposed LI-RADS ultrasound v2017[23] criteria for the 
definition of the risk on the basis of the features depicted at the radiological examination of the liver by 
ultrasound. The first step is to determine the presence/absence of a focal lesion and to subsequently identify 
the appropriate LI-RADS category: “US-1” (negative) defines the absence of lesions or the presence of 
clearly benign observations such as cysts, hemangiomas or skip areas around the gallbladder fossa; “US-2” 
(subthreshold) refers to a solid nodule which is not unequivocally benign, of diameter ≤ 1 cm and warrants 
short-term ultrasound surveillance; “US-3” (positive) takes into account lesions ≥ 10 mm in diameter, not 
unequivocally benign, which may warrant multiphase contrast enhanced imaging. This latter category also 
comprises new venous thrombosis. Considering the possible limitations of visibility at ultrasound associated 
with technical difficulties such as large patient body habitus or inability to cooperate, limited acoustic 
window, parenchymal heterogeneity and/or reduced beam penetration, LI-RADS ultrasound allows for 
the use of a “visualization score”: (1) no or minimal limitations which are unlikely to meaningfully affect 
sensitivity; (2) moderate limitations which may obscure small masses; and (3) severe limitations which 
significantly lower sensitivity for focal liver lesions. The category US-1 requires continuation of screening/
surveillance with ultrasound every six months; US-2 demands follow up by ultrasound after 3-6 months; 
US-3 warrants immediate multiphase contrast-enhanced MDCT/MRI or CEUS[23]. 
Contrast agents for ultrasound are biodegradable microbubbles that resonate under low-power ultrasound 
waves and generate harmonic signals. A contrast-specific ultrasound imaging mode, available on the 
majority of ultrasound scanners, highlights signals from microbubbles while applying specific pulse 
sequences which suppress signals from tissues. This stimulation of the microbubbles allows for the 
visualization of arterial hyper-enhancement and venous wash-out. Prospective studies have added evidence 
that different hepatic malignant lesions appear differently in CEUS and that their post-contrast behaviour is 
typical and reproducible[24]. As such, ACR has included a section dedicated to CEUS firstly in the version of 
LI-RADS of 2016 and has recently published a new edition[25,26]. Similar to those for injected MDCT/MRI, 
LI-RADS categories for CEUS are: CEUS LR-NC (uncategorizable), CEUS LR-TIV, CEUS LR-1 (definitely 
Figure 2. Ancillary features can help the radiologist to upgrade or downgrade of category the hepatic lesions. US: ultrasound; HCC: 
hepatocellular carcinoma
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benign), CEUS LR-2 (probably benign), CEUS LR-M (probably or definitely malignant but not specific for 
HCC), CEUS LR-3 (with intermediate risk of being malignant), CEUS LR-4 (probably HCC) and CEUS 
LR-5 (definitely HCC). The designation of categories CEUS LR-NC, LR-TIV, LR-1, LR-2, LR-M is possible in 
light of a basal observation of the lesion by ultrasound, whereas the designation of CEUS LR-3, LR-4, LR-5 
requires a post-contrast study [Figure 3]. 
Globally, the post-contrast behaviour of hepatic nodules in CEUS does not greatly differ from that observed 
in MDCT/MRI in terms of arterial hyperenhancement and venous/delayed washout. However, CEUS offers 
the possibility of studying the region of interest from a closer point of view and, by temporally monitoring 
the features of enhancement and of wash-out, it is possible to deduce additional and, sometimes, more 
Figure 3. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System. LR: Liver Imaging Reporting and Data System (LI-
RADS); US: ultrasound; CEUS: contrast-enhanced ultrasound; LR-NC: LI-RADS noncategorizable; TIV: tumor in vein; HCC: hepatocellular 
carcinoma; APHE: arterial phase hyperenhancement; LR-M: LI-RADS malignancy
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precise information with respect to MDCT/MRI. Obviously, as a counterpart, the global vision of the entire 
abdomen is lost, such that CEUS is not appropriate for tumor staging. In return, it can clearly depict key 
details such as the progressively centripetal and globular arterial hyperenhancement typical of hemangiomas 
(CEUS LR-1) [Figure 4], or the peripheral hyperenhanced rim visible in the early venous phase which is 
diagnostic of intrahepatic cholangiocarcinoma (CEUS LR-M), the early (< 60 s) and complete wash-out 
typical of metastases or of intrahepatic cholagiocarcinoma (CEUS LR-M) and which unequivocally differs 
from late (> 60 s) and partial wash-out which are diagnostic of HCC (CEUS LR-5) [Figure 5].
These are only some examples given in order to emphasize that CEUS has great potential to help adjudicate 
the right diagnosis, not only in the event of hepatic nodules of uncertain nature and as a complementary 
diagnostic tool after MDCT/MRI, but also as a first post-contrast examination of an observation of 
uncertain nature made at ultrasound (i.e., distinction between real nodule vs. fat sparing area/accumulation). 
In many situations CEUS can define the real nature of a lesion with high sensibility and specificity and 
can avoid an unneeded biopsy or, on the contrary, guide in its realization, in the presence of a hepatic 
Figure 4. The globular-like progressive centripetal arterial filling of hemangioma
Figure 5. In A and B, an HCC presents arterial hyperenhancement and late and mild washout with respect to the surrounding liver; on 
the contrary, in C and D, a malignant lesion of probable metastatic nature shows rim hyperenhancement together with early and marked 
wash-out. HCC: hepatocellular carcinoma; APHE: arterial phase hyperenhancement; LR: Liver Imaging Reporting and Data System (LI-
RADS); LR-M: LI-RADS malignancy
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lesion that undoubtedly exists but is scarcely visible with a basal ultrasound evaluation. In a recent study 
including 1,006 nodules, 820 (81%) HCC, 40 (4%) cholangiocarcinoma, 116(11%) regenerative/dysplastic 
nodules), Terzi et al.[27] demonstrated that the LR-5 category(52% of all nodules) was 98.5% predictive 
of HCC, with no risk of misdiagnosis for pure cholangiocarcinoma. Sensitivity for HCC was 62%. All 
LR-M nodules were malignant and the majority was of non-hepatocellular origin. The LR-3 category 
included 203 lesions [HCC 96 (47%)] and the LR-4 202 [HCC 173 (87%)]. These and similar results confirm 
the utility and the great potential of CEUS and justify the re-introduction of CEUS into guidelines. In 
the latest version of the EASL guidelines, CEUS was introduced in the diagnostic algorithm of HCC 
in cirrhotic patients but with a moderate degree of evidence and a weak degree of recommendation[28].
INTERPRETATION OF “NON-HYPERVASCULAR NODULES” IN CIRRHOSIS
The transformation of a regenerative nodule of cirrhosis into a dysplastic lesion involves a progressively 
reduced portal venous supply and a progressively increased arterial vascularization with sinusoidal 
capillarization and recruitment of unpaired arterioles; because of this reduced venous drainage, fat content 
frequently increases in early HCC but regresses in moderately differentiated HCC. Initially, dysplastic 
nodules show siderosis and copper retention, while during neoplastic transformation, Kupffer cell density 
decreases, and iron and copper accumulation are gradually lost[29]. Injected MDCT and, even better, MRI, 
can potentially depict all these changes in a rather sensible way and many efforts toward systematization 
of imaging description and classification have been made and are still made to promote their correct 
interpretation. In fact, the systems for radiological assessment of hepatic lesions like LI-RADS are based on 
the analogy between pathological characteristics and specific radiological features. The main limit of LI-RADS 
is that a diagnosis of HCC is reached only in the presence of arterial hyperenhancement. Thereby, a hepatic 
nodule that has a non-hypervascular arterial phase, even in the presence of ancillary features suggestive of 
malignancy, can never be defined as more than a “probable HCC” (LR-4) [Figure 6][21]. 
A study that has evaluated the enhancement pattern at multiphasic MDCT of 204 pathologically proven 
HCC smaller than 3 cm in diameter in cirrhotic patients, has found that the predominant enhancement 
patterns of HCC differ significantly depending on tumor size and cellular differentiation. Up to 46% of 
HCCs smaller than 10 mm in diameter do not show arterial hyperenhancement, while it is found in 70% of 
HCCs measuring 10-19 mm in diameter and in 75% of those measuring 20-29 mm. In line with these results, 
the association of arterial hyperenhancement and portal venous washout is observed only in 24% of 0-9 mm 
vs. 28% of 10-19 mm vs. 47% of 20-29 mm HCCs. Cell differentiation also plays an important role: arterial 
hyperenhancement is found in only 53% of well-differentiated HCCs, whereas the prevalence increases to 
79% in moderately differentiated HCCs, and was 60% in poorly differentiated HCCs. In conclusion, this and 
similar studies confirm that, although large nodules are easily diagnosed, the main difficulty in imaging of 
cirrhotic patients is the characterization of hepatic nodules smaller than 2 cm in diameter as they frequently 
do not show the “classical” arterial hyperenhancement[30].
Figure 6. From left to right: hepatic arterial phase, venous and late phase on multidetector computed tomography shows no enhancement 
of the tumor (due to the courtesy of Dr. Michele Di Martino)
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In light of these considerations, reaching a definitive non invasive diagnosis of HCC is still a challenge 
and MDCT and MRI with injection of extracellular agents (ECA) have proven to be relatively useless in 
the presence of small hypovascular nodules. The commercialization of gadoxetic acid has represented an 
important step towards the radiological diagnosis of borderline nodules because, it initially distributes in 
the extracellular fluid compartment, similar to extracellular contrast agents, and is subsequently taken up by 
functioning hepatocytes and excreted into the bile. Consequently, it provides both the benefits of dynamic 
imaging and the delayed hepatobiliary phase during which it is actively picked up by the hepatocytes 
through the organic anion transporting polypeptide (OATP) B1/8 transporter, a protein that is almost always 
lost in hepatocarcinogenesis [Figure 7]. A study conducted on surgically resected hepatocellular nodules 
has found a clear correlation between grade of histological de-differentiation, loss of expression of these 
transporters and appearance in MRI of a hypointensity in the hepatobiliary phase due to the lost capacity 
of intracellular uptake of the contrast agent, while the surrounding normal parenchyma remains strongly 
enhanced. Specifically, the authors evaluated 72 HCCs nodules to determine the correlation among the 
enhancement ratio on gadoxetic acid-enhanced MRI, the histological grade of tumour differentiation and 
the intensity of immunohistochemical OATP8 expression. They observed that all of the well, moderately 
and poorly differentiated HCCs showed a significantly decreased enhancement ratio compared with the 
background liver, with the exception of 6 moderately differentiated HCC which demonstrated a definitively 
increased enhancement ratio compared with the background liver. All of these nodules with “atypical 
behavior” showed increased OATP8 expression compared with the surrounding liver, while in all other 
HCCs a significant reduction in immunohistochemical OATP8 expression proportional to the grade of de-
differentiation was found[32].
These findings, confirmed by other studies, open a new scenario for the non-invasive diagnosis of hypovascular 
HCCs but the diagnostic role of hepatospecific contrast agents should be endorsed and formalized in 
international guidelines for radiological diagnosis of HCC, given that the last version of LI-RADS (v2017) 
still provides a single diagnostic algorithm for multiphase MDCT, MRI with ECA, and MRI with gadoxetate 
disodium. While initially combined for simplicity, the use of a common algorithm for all three imaging 
methods has a potentially important drawback: emerging evidence suggests that the assigned categories 
are modality-dependent, with different modalities assigning different categories to the same observation[33]. 
THE ROLE OF POSITRON EMISSION TOMOGRAPHY
The use of PET is still restricted in the field of HCC because of its low sensitivity. In a prospectively conducted 
study on 99 patients with histologically confirmed HCC who underwent 18F-fluoro-deoxyglucose positron 
Figure 7. From left to right: hepatic arterial phase of gadoxetic acid-enhanced magnetic resonance imaging shows homogeneous 
marked enhancement of the tumor; transitional phase shows washout of the contrast medium in the tumor with capsular enhancement; 
hepatobiliary phase shows marked hypointensity of the tumor relative to the liver parenchyma. Modified from Park et al .[31]
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emission tomography (FDG PET), none of the 7 patients with small tumors (< 2 cm in diameter), 18 of 42 
patients (43%) with tumors 2-5 cm in diameter, and 32 of 41 patients (78%) with tumors larger than 5 cm 
had positive findings for all index lesions. The sensibility increased in Barcelona clinic liver cancer staging 
system advanced stage, metastatic HCC and in patients with high levels of alphafetoprotein. All indexed 
lesions with positivity in FDG PET correlated with significantly lower survival with respect to patients with 
negative or partially positive PET[34]. As suggested by these results, other trials have demonstrated that PET 
positivity correlates with HCC aggressiveness, information which can be used to select, in a non-invasive 
way, candidates for liver transplantation or major liver resection[35]. In a retrospective study conducted on 111 
patients with HCC, liver transplantation was performed for 91 of these patients and all underwent PET before 
the intervention. The tumor recurrence rate after liver transplantation was 3.6% for patients with non- [18F]
FDG-avid PET tumors, but it was 54.3% for patients with [18F]FDG-avid PET tumors (P < 0.001). The 5-year 
recurrence-free survival rates were comparable for patients with tumors meeting the Milan criteria (86.2%) 
and patients with PET negative HCC exceeding the Milan criteria (81%) at liver transplantation, but these rates 
were significantly higher than the rate for liver recipients with [18F]FDG-avid advanced HCC (21%, P < 0.002)[36]. 
Preoperative evaluation of HCC with FDG PET has shown that well-differentiated and some moderately 
differentiated HCCs do not present FDG uptake exceeding that of the surrounding normal liver, whereas 
poorly differentiated and undifferentiated HCCs have positive PET findings. The standardized uptake value 
(SUV) max of sarcomatous HCC is much higher than that of poorly differentiated HCC. The entity of FDG 
captation of both sarcomatous HCC and combined HCC-cholangiocarcinoma is significantly associated 
with tumor differentiation, tumor size, microvascular invasion and with poor prognosis after surgery[37].  
A recently published study conducted on 207 consecutive patients with monofocal HCC undergoing hepatic 
resection used pre-operative FDG-PET imaging to stratify tumor aggressiveness and the albumin-bilirubin 
(ALBI) grade to stratify the hepatic reserve. The ALBI grade is a simple and objective measurement of liver 
function that uses only serum albumin and bilirubin levels and can be applied to all grades of chronic 
hepatic diseases, unlike Child Pugh score which is restricted to liver cirrhosis. The study demonstrated a 
strong correlation between the values of ALBI, the ratio tumorSUV/non-tumorSUV (TNR) and endpoints 
like overall survival and disease-free survival; whereas tumor size and tumor markers were not significant. 
Moreover, a high pre-operative TNR showed to be significantly associated with extrahepatic recurrence 
patterns[38]. 
The role of PET in the evaluation of tumor response to transarterial treatments has been investigated. 
Differently from the good sensitivity shown with cholangiocarcinoma and hepatic metastases of colorectal 
cancer treated with transarterial chemoembolization (TACE), PET has shown to be of little diagnostic value 
with respect to injected MDCT and MRI for HCC in intermediate stage treated with TACE. Only under 
specific circumstances, as in the case of strong PET positivity found in pre-treatment evaluation or the 
presence of a large intrahepatic tumor burden treated with yttrium90-radioembolization has PET shown 
accuracy in early evaluation of tumor response[39].
In conclusion, even if 18F-FDG-PET does not acquire a definite role in guidelines due to its low sensibility 
in revealing HCC, it has proved useful in specific instances, such as prior to listing patients with large 
HCC for liver transplantation, before major resections or when there is suspicion of an extra-hepatic 
neoplastic diffusion. In the last EASL guidelines FDG PET-scan is not recommended for early diagnosis 
of HCC because of the high rate of false negative cases but uptake on 18F-FDG-PET seems to be of 
potential prognostic value. Therefore, it may facilitate the selection of patients for surgical resection or liver 
transplantation[28].
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HCC IN NON-CIRRHOTIC PATIENTS
HCC occurring in non-cirrhotic livers is uncommon and the clinical presentation is very different from that 
observed in cirrhosis. Since the tumor occurs in subjects not known to be at risk of HCC, the diagnosis is 
generally delayed and therefore the tumor is larger than commonly seen in cirrhotic patients. The problem 
is whether the radiological characteristics that are decisive for the diagnosis of HCC on cirrhosis can be 
translated in this different clinical situation. Di Martino et al.[40] retrospectively reviewed histopathological 
and laboratory findings of 30 non-cirrhotic patients with 32 HCCs. MDCT and gadobenate dimeglumine 
enhanced MRI were evaluated. Imaging patterns were compared directly with HCC findings in a matched 
group of cirrhotic patients. The imaging appearance at MDCT and contrast-enhanced MRI was typical in 
27 (84.3%) and 28 (87.5%) cases, respectively. Most lesions presented as a well-differentiated large solitary 
mass, with well-defined margins, areas of necrosis and peripheral capsule. No significant differences in HCC 
pattern were observed between cirrhotic and non-cirrhotic liver. But in the last EASL guidelines in non-
cirrhotic liver, imaging alone is not considered sufficient and histological assessment is required to establish 
the diagnosis of HCC and has the additional advantage of providing further information regarding the 
nontumourous liver tissue[28].
MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS FOR THE EVALUATION OF 
HCC RESPONSE TO TREATMENTS
Radiology plays an important role not only for the diagnosis but also for the evaluation of the response 
both to locoregional and to systemic treatments of HCC. Until 2010, EASL and AASLD have recommended 
Response Evaluation Criteria In Solid Tumors (RECIST) and WHO criteria in their guidelines for the 
management of HCC for the evaluation of response to treatment. The application of these criteria requires 
the measurement of the major diameter of the HCC nodule/s. However, because of the relevance of the 
necrotic portion of a treated nodule with respect to its global size, a new version of RECIST modified 
for HCC, formally taking into account only the vital tissue in each HCC lesion, was published in 
2010[41]. These criteria have been endorsed in 2012 by EASL and European Organisation for Research 
and Treatment of Cancer (EORTC) in their guidelines and are currently still the gold standard for the 
assessment of radiological response, confirmed in the last version of EASL guidelines[4,28]. The application 
of modifiedRECIST (mRECIST) requires taking into account those HCC nodules which are clearly visible, 
measurable and showing the typical “hallmark of wash-in and wash-out” as “target lesions”, while all 
the HCC localizations not definitively measurable or with an atypical post-contrast appearance such as 
intrahepatic lesions which show infiltrative behavior with poorly defined margins and poorly defined 
hyperenhancement, malignant thrombosis, neoplastic ascites, adenopathies, very small and/or numerous 
diffuse lesions, are to be considered “non target lesions”. According to mRECIST, only “target lesions” can 
undergo a dimensional evaluation of their vital portion (tissue showing arterial hyperenhancement and 
venous/delayed washout) by the measurement of its longest diameter. The response assessment is to be based 
on the comparison of this size before and after the treatment. On the contrary, “non target lesions” can be 
monitored over time on the basis of their absence/presence (i.e., neoplastic ascites) or of their measurement 
according to RECIST (longest diameter of the lesion as a whole). With respect to “target lesions”, the possible 
responses are: a complete response (CR) defined by the disappearance of all arterial hyperenhancement in 
all target lesions; a partial response (PR) in the case of a reduction of at least 30% in the sum of the diameters 
of the vital portions of the target lesions; progressive disease (PD) if an increase of at least 20% in the sum of 
the longest diameters of all target lesions is observed; and stable disease (SD) if neither PR nor PD definition 
criteria can be satisfied [Table 2]. 
With respect to “non-target lesions”: a CR will correspond to the disappearance of all enhancing tissue in 
all of them, an incomplete response/SD is defined by the persistence of vital tissue in at least one “non target 
lesion”; a PD is defined by the appearance of a new lesion or the unequivocal worsening of at least one of the 
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known “non target lesions”. After having assigned a definition for each category of lesions (target/non target) 
it will be possible to define the “overall response according to mRECIST” by cross-referencing each response 
obtained in the two categories of lesions as shown in Table 3.
Subsequent publications have reported a good correlation between the objective response evaluated with 
mRECIST and overall survival, both after the application of loco-regional treatments[42] and also after 
systemic therapies[43]. However, the application of mRECIST criteria in clinical practice is sometimes 
challenging due to their complexity and also because it is not rare to find an HCC represented exclusively 
by “non target lesions” or by nodular hepatic lesions which do not exhibit the traditional post-contrast 
“HCC hallmark”. As such, their use is contraindicated. Finally, it remains to be established that mRECIST 
is superior to RECIST and a comparative evaluation is therefore required[44]. A recent analysis of two phase 
II trials in patients treated with sorafenib or nintedanib showed that both RECIST and mRECIST response 
were correlated with overall survival, with similar discriminative abilities in multivariate analysis[45]. It was 
also shown that mRECIST and RECIST are equivalent in the evaluation of progression, which is the most 
important endpoint in regards to therapeutic decisions.
IN THE FUTURE
The development of artificial intelligence will probably allow in the future to improve the interpretation 
of images obtained with the ultrasound, MDTC or MRI with contrast medium limiting diagnostic errors 
computer-aided diagnosis (CAD) is one of the most important research topics in radiology and medicine. 
A software based on the recognition of the contrast features of the lesions calculates the probability that 
they are benign or malignant. Moga et al.[46] developed a CAD prototype used to analyze 97 videos of 
good quality CEUS [34% HCC, 12.3% hypervascular metastases, 11.3% hypovascular metastases, 24.7% of 
hemangiomas, 17.5% of focal nodular hyperplasia (FNH)]. The authors evaluated the diagnostic performance 
of two young doctors, two experts and CAD in the diagnosis of benign vs. malignant lesions. The CAD was 
useful in improving the diagnostic skills of young doctors, especially when integrated with clinical data, but 
was lower than the skills of experienced doctors. The most frequently misdiagnosed lesions were FNH and 
HCC[46].
Kim et al.[47] developed and evaluated a CAD program for hepatic lesions on MRI for the classification of 
HCC risk according to the LI-RADS criteria. MRI images of the livers of 41 patients with hyperenhancing 
liver lesions classified as LR 3, 4 and 5 were evaluated by two radiologists. The agreement on the classification 
of lesions by radiologists and CAD was 76%-83%, while the agreement between radiologists was 78%.
Table 2. Comparison between Response Evaluation Criteria In Solid Tumors and Modified Response Evaluation Criteria In 
Solid Tumors for target lesions[41]
RECIST mRECIST for HCC
CR = Disappearance of all target lesions CR = Disappearance of any intratumoral  arterial enhancement in all 
target lesions
PR = At least a 30% decrease in the sum of diameters of all target 
lesions, taking as reference the baseline sum of the diameters of 
target lesions 
PR = At least 30% decrease in the sum of diameters of viable 
(enhancement in the arterial phase) target lesions, taking as 
reference the baseline sum of the diameters of target lesions 
SD = Any cases that do not qualify for either partial response or 
progressive disease
SD = Any cases that do not qualify for either partial response or 
progressive disease
PD = An increase in 20% in the sum of diameters of target lesions, 
taking as reference the smallest sum of the diameters of target 
lesions recorded since treatment started
PD = An increase in 20% in the sum of diameters of viable 
(enhancing) target lesions, taking as reference the smallest sum of 
the diameters of target lesions recorded since treatment started
RECIST: Response Evaluation Criteria In Solid Tumors; mRECIST: Modified Response Evaluation Criteria In Solid Tumors; HCC: 
hepatocellular carcinoma; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease
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